Rinkey Investments’s Protalix BioTherapeutics PLX Stock Holding History

Rinkey Investments’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	–	–	186
2021 Q4	$0	Buy	+100	New	+$105	﹤0.01%	273

Other funds holding PLX

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Rinkey Investments's PLX Position: Q1 2022 in Review

Rinkey Investments sold out of Protalix BioTherapeutics (PLX) in Q1 2022, closing a stake of 100 shares.

Rinkey Investments first reported a position in PLX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 32 funds tracked by Wall St. Rank hold PLX as of Q1 2022.

Rinkey Investments reported no remaining Protalix BioTherapeutics position as of Q1 2022 after selling out during the quarter.
Rinkey Investments sold 100 Protalix BioTherapeutics shares in Q1 2022.
Rinkey Investments first reported a position in Protalix BioTherapeutics in Q4 2021 and held it in 1 quarter.
Rinkey Investments's Protalix BioTherapeutics position peaked at $0 in Q4 2021.
32 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2022.

Based on Rinkey Investments's 13F filing for Q1 2022, filed 9 May 2022.